Rhabdomyolysis developing secondary to atorvastatin therapy in a patient with liver cirrhosis

7Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Atorvastatin is a lipid lowering agent that is widely used worldwide. Rhabdomyolysis is a rare but serious side effect that may lead to renal failure and dangerous electrolyte abnormalities in patients with decreased hepatic clearance of atorvastatin. We herein report the case of a patient with liver cirrhosis receiving atorvastatin therapy for ischemic heart disease and hyperlipidemia who developed rhabdomyolysis and acute renal failure. © 2013 The Japanese Society of Internal Medicine.

Cite

CITATION STYLE

APA

Eshraghian, A., & Kamyab, A. A. lam. (2013). Rhabdomyolysis developing secondary to atorvastatin therapy in a patient with liver cirrhosis. Internal Medicine, 52(7), 823–825. https://doi.org/10.2169/internalmedicine.52.9272

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free